Patent Suit Or Smear Campaign? Automated Pap Firms Raise Legal Stakes
This article was originally published in The Gray Sheet
TriPath accuses Cytyc of unlawful business interference in an unfair competition/patent infringement lawsuit filed June 17
You may also be interested in...
Digene does not plan to extend a co-promotion pact with Cytyc for its DNAwithPap test after signing on PDI to set up a U.S. physician detailing organization
TriPath expects narrower price differences between its SurePath and Cytyc's ThinPrep Pap test alternative over the long-term after receiving FDA sign-off on labeling that puts the tests on par for efficacy
Digene will be required to submit additional clinical data to FDA to support its application for use of TriPath's SurePath test pack as a specimen collection medium for the Hybrid Capture 2 (HC2) human papillomavirus (HPV) test